Clinical Trials Directory

Trials / Unknown

UnknownNCT03050047

A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors

A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) in Patients With Advanced Solid Tumors

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
15 (actual)
Sponsor
Biocad · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) in Patients with Advanced Solid Tumors

Conditions

Interventions

TypeNameDescription
BIOLOGICALBCD-100Anti-PD1 monoclonal antibody

Timeline

Start date
2016-08-30
Primary completion
2017-07-01
Completion
2018-11-01
First posted
2017-02-10
Last updated
2018-08-31

Locations

4 sites across 1 country: Russia

Source: ClinicalTrials.gov record NCT03050047. Inclusion in this directory is not an endorsement.

A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors (NCT03050047) · Clinical Trials Directory